Targeting prostate cancer with specialized drug activation
Activation of Drug and Biologic Conjugates by Click Chemistry and their Tumor-selective Targeting for Prostate Cancer Suppression
['FUNDING_R21'] · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · NIH-11049022
This study is exploring a new way to treat advanced prostate cancer by using a special drug that only targets cancer cells, aiming to kill the cancer without hurting healthy cells, and it's designed for men dealing with this tough condition.
Quick facts
| Phase | ['FUNDING_R21'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF TEXAS HLTH SCIENCE CENTER (nih funded) |
| Locations | 1 site (SAN ANTONIO, UNITED STATES) |
| Trial ID | NIH-11049022 on ClinicalTrials.gov |
What this research studies
This research investigates a new method to treat advanced prostate cancer by activating a special drug only within tumor cells. The approach uses a technique called click chemistry to release the drug in cancerous tissues while minimizing harm to healthy cells. By focusing on a compound that reacts with substances found in cancer cells, the goal is to effectively destroy cancer cells without the side effects typically associated with chemotherapy. This study will test the effectiveness of these drug conjugates in preclinical models of castration-resistant prostate cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with castration-resistant prostate cancer who have limited treatment options.
Not a fit: Patients with early-stage prostate cancer or those who do not have castration-resistant prostate cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and targeted treatments for patients with advanced prostate cancer, reducing side effects and improving outcomes.
How similar studies have performed: Previous research has shown promise in using targeted drug delivery systems in cancer treatment, suggesting that this approach may also be effective.
Where this research is happening
SAN ANTONIO, UNITED STATES
- UNIVERSITY OF TEXAS HLTH SCIENCE CENTER — SAN ANTONIO, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: CHATTERJEE, BANDANA — UNIVERSITY OF TEXAS HLTH SCIENCE CENTER
- Study coordinator: CHATTERJEE, BANDANA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: advanced prostate cancer, androgen independent prostate cancer, androgen indifferent prostate cancer